Jerry Williamson has been appointed as the new president of Biacore, replacing Thomas Wida, who is leaving the company, Biacore International said on this week. Williamson joins the Uppsala, Sweden-based company from Beacon BioPartners, a consultancy focusing on the life sciences sector. Until recently, he was the president of Pyrosequencing. Biacore said it will incur approximately SEK3.2 million ($430,000) for the termination of Wida’s contract.
Argeris Karabelas will become the new chairman of the board of directors of Human Genome Sciences next month, replacing William Haseltime after his retirement, the company said this week. Karabelas is a partner of investment firm Care Capital and has been a director of Human Genome Sciences since 2002. He holds a PhD in pharmacokinetics from the Massachusetts College of Pharmacy.
In addition, Human Genome Sciences has promoted Craig Rosen to president and chief operating officer, from president for research and development. Laura D’Andrea Tyson will retire from the company’s board of directors to devote more time to other responsibilities.
Silvano Fumero and Larry Respess have joined the board of directors of Nautilus Biotech, the Paris-based company said last week. Respess, an intellectual property lawyer, is senior vice president and general counsel of Nanogen. Fumero, who will chair the board, is CEO of Creabilis Therapeutics, a drug discovery company based in Canavese, Italy.
Susan Lindquist will resign as president of the Whitehead Institute to focus on her laboratory and research, effective “on or about” Nov. 1, said the Institute’s board of directors in a statement last week.